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Abstract: In 2007, a hydrogel histrelin implant was approved for the treatment of children 
with central precocious puberty (CPP). Children with CPP commonly have reduced height 
potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. 
Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for 
improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, 
histrelin, was ﬁ  rst developed for use in men with prostate cancer. A once yearly histrelin subcu-
taneous implant was subsequently developed for the treatment of children with CPP. Studies to 
date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients 
treated up to 2 years. The most common adverse effects of the implant relate to implant site pain 
or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly 
used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish 
continued efﬁ  cacy and safety beyond 2 years of treatment, the histrelin implant appears to be 
an attractive option for GnRHa treatment in patients with CPP.
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Introduction
Central precocious puberty (CPP) refers to the early activation of the hypothalamic-
pituitary-gonadal (HPG) axis leading to secondary sexual characteristics in girls prior 
to age 7.5 to 8 and in boys prior to age 9.1 Children with CPP have advanced skeletal 
maturity that can result in compromise of ﬁ  nal adult height. Gonadotropin-releasing 
hormone analogs (GnRHa) have been used since the early 1980s to suppress the HPG 
axis in children with CPP.2 Halting puberty in this manner alleviates further bone 
maturation from sex steroid exposure, resulting in improved predicted adult heights.3 
Standard treatment of CPP has consisted of depot GnRHa that require injections at 
approximately 4-week intervals.4 The histrelin subcutaneous implant developed for 
the treatment of CPP provides an alternative treatment to these frequent injections.
Background
Histrelin acetate, a potent synthetic GnRHa, has been available in the United States 
since 1991 for the treatment of central precocious puberty. However, since it required 
daily administration, it has never been widely used. A hydrogel implant was developed 
which allowed for the sustained release of histrelin by continuous simple diffusion. 
By manipulating the water content of the hydrogel capsule, the rate of release can be 
set to a predetermined amount.5
A histrelin hydrogel implant was initially developed for the purpose of obtain-
ing medical castration in men with metastatic prostate cancer. This 50 mg histrelin Drug Design, Development and Therapy 2009:3 2
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implant was designed to release 60 μg of histrelin daily. In an 
initial study comprising 15 men, a single implant was placed 
in 8 men and 2 implants were placed in 7 men. Although 
4 patients had a rise in prostate speciﬁ  c antigen (PSA) levels, 
all subjects had complete suppression of testosterone and 
luteinizing hormone (LH) levels. “Challenge tests” done 
in 8 patients with ﬂ  utamide and a bolus of GnRH at 1 year 
demonstrated testosterone and LH concentrations at the 
lower limits of assay sensitivity. Suppression was observed 
for the duration of implant placement which was as long as 
30 months in some patients.6 Similar results were reported in 
27 additional subjects who received 4 implants, 2 implants, 
or a single implant. Implants were replaced on an annual 
basis. All patients had suppression of LH and testosterone 
during the treatment except 1 patient who had a rise of LH 
but continued suppression of testosterone and PSA.7
A phase III, open-label, ﬁ  xed-dose multicenter study of 
138 men with advanced prostate cancer was subsequently 
conducted. By week 4 after implantation, all subjects with 
baseline measurable testosterone levels had suppressed 
levels. PSA and LH levels were also suppressed. One hundred 
and ten patients underwent reimplantation after 52 weeks and 
were followed for 60 weeks. A surge in LH or testosterone 
levels was not seen with reimplantation.8 A subset of these 
patients participated in pharmacokinetic assessments. Peak 
histrelin concentrations were achieved rapidly (median time 
to peak was 12 hours) followed by a slow decline in levels 
over the 52-week time period. Overall, the implant demon-
strated consistent drug delivery with a mean serum histrelin 
concentration of 0.265 ng/mL.
The results of these studies led investigators to propose 
the development of a similar implant for use in children 
for the treatment of central precocious puberty. A 50 mg 
histrelin hydrogel implant designed to release 65 μg daily 
was subsequently developed. Figure 1 demonstrates the 
appearance and size of the histrelin subcutaneous implant, 
while existing studies using this device for the treatment of 
CPP are reviewed below.
Studies in children
A pilot study investigated the use of this implant in eleven 
girls with central precocious puberty who were already being 
treated with standard GnRHa therapy. Mean age at time of 
implant was 8.5 years (range 3.75–11), and each patient 
received 1 or 2 implants. Five girls had implants replaced 
at 9 months with a new implant placed at the same site. Six 
girls had implants left in place for 15 months. Participants 
were seen at 3-month intervals and GnRH-stimulation tests 
were done at the 6- and 9-month visits in all patients and 
at 12- and 15-month visits for those followed for 15 months. 
All patients had clinical evidence of good treatment response, 
and all had consistently suppressed basal and stimulated 
gonadotropins and estradiol. No differences were seen in 
girls treated with 1 vs 2 of the implants.4
This study was followed by a multicenter, open-label, 
prospective study to further evaluate the safety and efﬁ  -
cacy of the histrelin subcutaneous implant for the treat-
ment of CPP. Thirty-six subjects with CPP, including 
20 treatment-naïve and 16 previously treated patients, 
were followed for 1 year after placement of the histrelin 
implant. Both treatment groups demonstrated signiﬁ  cantly 
decreased peak stimulated LH concentrations at one month. 
Suppression (LH   4 mIU/mL) was maintained throughout 
the 12 months. In addition, the rate of skeletal maturation, 
Figure 1 Appearance and size of the histrelin subcutaneous implant. Numbers on the ruler represent 1-inch markings (1 inch = 25 mm).Drug Design, Development and Therapy 2009:3 3
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as assessed by the ratio of bone age to chronological age, 
declined signiﬁ  cantly over the 12 months. Secondary sexual 
characteristics as described by Tanner staging did not prog-
ress in either group. Predicted adult height did not change 
in either group after one year.9 The results of this study led 
to FDA approval of the implant for treatment of CPP in 
children in May 2007.
Results from a second year of treatment in 31 subjects 
who elected to receive a new histrelin implant for continued 
treatment of CPP have also been reported. Of these subjects, 
29 were girls and 18 were treatment naïve at the time of the 
initial histrelin implantation. Peak stimulated LH declined 
further from 12 to 24 months in both the treatment naïve and 
previously treated patients. Predicted adult height improved 
in girls from 12 months to 24 months (156.3 cm to 158.4 cm 
[p = 0.007]).10 Results from studies conducted in children 
with CPP are summarized in Table 1.
Safety and tolerability
The most common adverse events in children treated 
with the histrelin implant relate directly to the implant 
insertion or removal. Implant site reactions such as pain 
and bruising at the time of implantation are reported in 
up to 61% of patients.9,10 In the pilot study, there was 1 
case each of a minor local infection requiring antibiotic 
therapy, inadvertent suture insertion into the implant, and 
implant extrusion 6 weeks after implantation.4 None of 
these problems have been noted in the subsequent studies, 
likely due to standardization of the implantation procedure. 
Difﬁ  culty with implant removal has also been reported, 
including need for ultrasound localization and breakage 
of the implant during explantation.9 Scarring (one keloid) 
at the site of the implant was reported in 2 patients in the 
2-year study.10 There have been no reported signiﬁ  cant 
abnormalities in hematology parameters, urinalysis, or 
other clinical laboratory evaluations.4,9 In 4 subjects who 
were treated for 12 months and evaluated 1 month after 
removal of the implant, histrelin levels were undetectable, 
and stimulated LH values had risen to pubertal ranges.9
Clinical studies indicate that the implant is well tolerated 
by patients. Reduced pain or discomfort and less disruption 
of activities as compared with depot GnRHa was noted by a 
quality of life questionnaire in the pilot study.4 In addition, 
31 of 32 patients continuing on GnRHa therapy chose to 
receive a second implant after 12 months in the phase III 
trial.9  The appearance of a typical scar 6 months after implan-
tation is seen in Figure 2.
Costs and barriers to access
The average wholesale price of the histrelin implant is 
US$16,800.11 The cost related to placement and removal 
of the histrelin implant is not included in this price. Cost of 
these procedures varies depending on the clinical setting and 
type of anesthesia utilized. In our center at Indiana University 
Table 1 Results of studies of the histrelin implant for the treatment of central precocious puberty
Study Number of 
patients







Pilot study4 11 (all girls) Baseline 1.3 ± 1.34 
6 mo 0.2 ± 0.06* 
9 mo 0.25 ± 0.08* 
12 mo 0.28 ± 0.08* 
24 mo 0.25 ± 0.08*
BA–CA: 
Baseline 1.7 ± 0.5 
9 mo 0.6 ± 0.4
Baseline 2.8 ± 1.7 
9 mo −3.1 ± 2.2
Minor local infection (1) 
Suture inserted into implant (1) 
Spontaneous extrusion at 
6 weeks (1)
Phase III study9 36 (33 girls) 
(20 naïve)
Naïve group 
Baseline 28.2 ± 20 
1 mo 0.8 ± 0.4* 
Pretreated group 
Baseline 2.1 ± 2.1 
1 mo 0.5 ± 0.3*
Δ(BA/CA) 
Baseline to 
12 months: Naïve 
group –0.08 ± 0.08* 
Pretreated group 
–0.09 ± 0.06* 
All –0.08 ± 0.07*
Naïve group 
12 mo –1.8 ± 2.5 
Pretreated group 
12 mo 0.6 ± 2.3
Implant site reactions (18) 
Implant broken upon removal 
(7) Ultrasound localization 
needed for removal (1)
Two-year results10 31 (29 girls) 
(18 naïve)
Naïve 
12 mo 0.92 ± 0.58 
24 mo 0.51 ± 0.33* 
Pretreated group 
12 mo 0.74 ± 0.50 
24 mo 0.45 ± 0.35*
Δ(BA/CA) 
12 to 24 months: 
–0.07 ± 0.04*
12 mo –0.42 ± 2.4 
24 mo –1.75 ± 3.05*
Implant site reactions (19) 
Ultrasound localization needed 
for removal (3) Breakage upon 
removal (5) Scar (2 reported, 
1 keloid)
*statistically signiﬁ  cant change from baseline (p   0.05).
Abbreviations: BA, bone age;  CA, chronological age;  LH, luteinizing hormone;  SDS, standard deviation score;  Δ(BA/CA),  change in ratio of bone age to chronological age.Drug Design, Development and Therapy 2009:3 4
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the implants are placed by a pediatric surgeon in a outpatient 
clinic setting with use of local anesthesia and distraction 
techniques. Conscious sedation and general anesthesia have 
been utilized at other medical centers.9 Certainly, the cost 
of implantation would be expected to be higher using these 
means of anesthesia.
By comparison, the average wholesale of depot leup-
rolide ranges from approximately US$8,936 to $17,868 
annually depending on the dose required to obtain adequate 
suppression.11 These ﬁ  gures do not take into account the 
costs related to administration of the medication, the cost of 
potential time lost from work for parents and guardians due 
to frequent visits for medication administration, or the cost 
of transportation for these visits.
Insurance coverage varies by plan and requires prior 
authorization. In our experience at Riley Hospital for 
Children, private insurance companies have generally been 
willing to offer comparable coverage of the implant to depot 
leuprolide injections after consideration of the comparative 
costs between the two treatments and the problematic issues 
that can arise from the need for depot leuprolide injections 
every 3 to 4 weeks. These issues include non-compliance, 
patient discomfort from the injections, and additional costs 
related to administration as described previously. In con-
trast, Indiana Medicaid has balked at approving the implant 
device.
Unanswered questions
Additional issues yet to be addressed about the use of the 
histrelin implant for CPP include questions about the long 
term effects of this treatment option. While the implant has 
demonstrated safety and efﬁ  cacy in the studies to date, it is 
possible that undesirable treatment effects may emerge in 
the future.
Concerns regarding long term reproductive function after 
treatment with GnRHa have been addressed by multiple 
investigators with biochemical demonstration of reversibil-
ity of HPG suppression by one year after discontinuation of 
therapy.12–14 With the profound suppression of peak LH levels 
seen in patients treated with the histrelin implant, concerns 
that the HPG axis could be oversuppressed have been raised. 
Based on the recovery of LH levels to the pubertal range after 
removal of the one year histrelin implant in the 4 patients 
who discontinued GnRHa treatment in the phase III trial, it 
seems unlikely that patients would be at increased risk for 
long term reproductive problems.
Another possible concern related to extreme hypothalamic-
pituitary-gonadal axis suppression is a theoretical detrimental 
effect on growth velocity. At present, the degree of suppres-
sion needed to achieve optimal beneﬁ  t in terms of height is 
unknown.15 While the observed improvement in predicted 
adult height after 2 years of treatment with the histrelin implant 
is reassuring, long term follow-up to ﬁ  nal adult height is 
needed to fully address this issue.
Children treated with GnRHa therapy often have 
increased body mass index (BMI), often prior to GnRHa 
therapy. This can progress to frank obesity in some 
patients12 although GnRHa treatment in general has not 
been found to cause or aggravate obesity.16 Interestingly, 
in the 2-year results with the histrelin implant, mean BMI 
Figure 2 Appearance of typical scar seen 6 months after implantation of histrelin implant.Drug Design, Development and Therapy 2009:3 5
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declined over the 12- to 24-month treatment period.10 
Further study will be needed to assess whether this may 
be a particular treatment advantage related to this form of 
GnRHa therapy.
Another area for further investigation deals with the 
issue of implantation by non-surgical practitioners. Implant 
placement requires only a small incision, and then a speciﬁ  -
cally designed trocar allows for placement of the hydrogel 
capsule under the skin. Non-surgical practitioners could be 
trained to perform the procedure in the ofﬁ  ce setting. While 
this might reduce the cost of having the implant placed, 
it is possible that an increased incidence of implant site 
adverse reactions may be seen if non-surgical practitioners 
with less procedural experience perform the implantation. 
Similar questions should be addressed about the removal 
process as well.
Conclusion
Results from studies to date support the use of the histrelin 
implant as a safe, effective, and well-tolerated option for the 
treatment of children with CPP. Further study will provide 
additional information about long term safety and effective-
ness and may be useful in providing solutions to overcome 
barriers to treatment.
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